Yohann Loriot

Nov 21, 2024 | cell.com | Habib Hamidi |Yasin Senbabaoglu |Niha Beig |Juliette Roels |Cyrus Manuel |Xiangnan Guan | +26 more

Keywordsurothelial carcinomatranscriptomicsmolecular heterogeneityPD-L1 blockadepatient stratificationdigital pathologyGet full text accessLog in, subscribe or purchase for full access. References1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J. 1992; 11:3887-38952. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...

Oct 28, 2024 | acsjournals.onlinelibrary.wiley.com | Peter O’Donnell |Yohann Loriot |Tibor Csöszi |Nobuaki Matsubara

INTRODUCTION Approximately 30%–50% of patients with advanced urothelial carcinoma (UC) are ineligible to receive cisplatin-based chemotherapy because of baseline characteristics such as advanced age, renal dysfunction, poor performance status, and other medical comorbidities.1, 2 Although numerous patients in this population can still receive carboplatin-based treatment, many are deemed ineligible for any cytotoxic platinum-based chemotherapy by their treating physicians.3, 4 Because no...

Feb 29, 2024 | nature.com | Yohann Loriot |Giovanni Brandi

AbstractFibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal development and contributes to tissue and whole-body homeostasis, but can also promote tumorigenesis. Various agents, including pan-FGFR inhibitors (erdafitinib and futibatinib), FGFR1/2/3 inhibitors (infigratinib and pemigatinib), as well as a range of more-specific agents, have been developed and several have entered clinical use.

Nov 2, 2023 | futuremedicine.com | Yohann Loriot |Anne O'Hagan |Arlene Siefker-Radtke |Gustave Roussy

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereLink to original article hereAcknowledgmentsThe authors of this article would like thank the participants who took part in this study and their families, the investigators, co-investigators, and staff at each of the study centers, as well as the Janssen BLC2001 study team.

Jun 1, 2023 | urotoday.com | Yohann Loriot

In this talk, Yohann Loriot discusses the work of the Groupe d'Etude des Tumeurs Uro-Génitales (GETUG), a French clinical research network focused on GU oncology. He explains GETUG's structure, a multidisciplinary group composed of medical oncologists, radiation oncologists, urologists, pathologists, statisticians, and radiologists. Loriot emphasizes the organization's commitment to conducting clinical trials on rare tumors and penile tumors, among others.